prolymphocytic leukemia (Cancer)
Information
- Disease name
- prolymphocytic leukemia
- Disease ID
- DOID:1039
- Description
- "A chronic lymphocytic leukemia that is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen." [url:https\://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/what-is-non-hodgkin-lymphoma/prolymphocytic-leukemias]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02005289 | Active, not recruiting | Phase 2 | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | January 17, 2014 | December 31, 2024 |
| NCT04191187 | Active, not recruiting | Phase 2 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | December 6, 2019 | February 2025 |
| NCT02722668 | Active, not recruiting | Phase 2 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | May 15, 2017 | December 2029 |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT02296918 | Active, not recruiting | Phase 1 | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | December 22, 2014 | September 6, 2027 |
| NCT02029443 | Active, not recruiting | Phase 1/Phase 2 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | January 30, 2014 | September 6, 2027 |
| NCT02007044 | Active, not recruiting | Phase 2 | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | December 6, 2013 | June 30, 2026 |
| NCT01589302 | Active, not recruiting | Phase 2 | PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia | May 21, 2012 | December 31, 2024 |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00278213 | Completed | Phase 2 | Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | September 2002 | December 2009 |
| NCT01484015 | Completed | Phase 1 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | February 2011 | October 2012 |
| NCT00309842 | Completed | Phase 2 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | July 28, 2005 | November 22, 2019 |
| NCT00343798 | Completed | Phase 1 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | April 2006 | |
| NCT02661035 | Completed | Phase 2 | Allo HSCT Using RIC for Hematological Diseases | March 9, 2017 | May 29, 2023 |
| NCT02556931 | Completed | Phase 2 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | December 2015 | April 2021 |
| NCT01515176 | Completed | Phase 1/Phase 2 | Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | January 2012 | July 19, 2016 |
| NCT00735930 | Completed | Phase 1 | Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | August 2008 | November 2014 |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT00898079 | Completed | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | October 13, 2003 | June 30, 2018 | |
| NCT01029366 | Completed | Phase 1 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | March 17, 2010 | May 2016 |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT02530515 | Completed | Phase 2 | Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia | December 18, 2015 | April 30, 2018 |
| NCT01093586 | Completed | Phase 2 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | September 2007 | December 2015 |
| NCT01527045 | Completed | Phase 2 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | September 25, 2012 | April 2019 |
| NCT01129180 | Completed | Phase 1 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | May 2010 | December 2012 |
| NCT01129193 | Completed | Phase 1 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | May 4, 2010 | January 7, 2017 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01212380 | Completed | Phase 1 | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) | October 2010 | September 2015 |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT01231919 | Completed | Phase 1 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | January 2011 | |
| NCT01251575 | Completed | Phase 2 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | December 1, 2010 | February 11, 2019 |
| NCT01254578 | Completed | Phase 1 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | November 24, 2010 | November 9, 2012 |
| NCT00005803 | Completed | Phase 1/Phase 2 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | September 1999 | October 2018 |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00060424 | Completed | Phase 2 | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia | March 2003 | September 22, 2010 |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT03097770 | Completed | Phase 1/Phase 2 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | April 1, 2017 | January 31, 2020 |
| NCT00104858 | Completed | Phase 2 | Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | December 2004 | March 30, 2018 |
| NCT05805605 | Recruiting | Phase 2 | Allo HSCT Using RIC and PTCy for Hematological Diseases | May 1, 2023 | October 22, 2028 |
| NCT01962636 | Recruiting | N/A | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | December 2016 | October 2025 |
| NCT03246906 | Recruiting | Phase 2 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | September 11, 2017 | October 11, 2026 |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT04195633 | Recruiting | Phase 2 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | January 25, 2021 | December 31, 2026 |
| NCT04411043 | Recruiting | Observatory of Prolymphocytic Leukemia T | July 1, 2020 | June 1, 2025 | |
| NCT01419795 | Terminated | Phase 2 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant | May 2012 | |
| NCT00387426 | Terminated | Phase 2 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | September 2006 | February 2009 |
| NCT00281931 | Terminated | Phase 2 | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia | September 1999 | October 2006 |
| NCT02991898 | Terminated | Phase 2 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | February 16, 2017 | June 20, 2019 |
| NCT00098488 | Terminated | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | April 2005 | |
| NCT00098371 | Terminated | Phase 2 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | April 2005 | November 2012 |
| NCT00005786 | Terminated | N/A | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | January 2001 | |
| NCT01629511 | Terminated | Phase 1/Phase 2 | Allogeneic Stem Cell Transplant for CLL | November 21, 2012 | April 25, 2018 |
| NCT01126502 | Terminated | Phase 1 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | May 2010 | June 2012 |
| NCT01076556 | Terminated | Phase 1 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | April 2010 | |
| NCT00612612 | Terminated | Phase 1 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | January 2008 | |
| NCT01735604 | Unknown status | Phase 1/Phase 2 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | January 2013 | October 2018 |
| NCT02303392 | Unknown status | Phase 1 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | March 11, 2015 | December 31, 2022 |
| NCT01864889 | Unknown status | N/A | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 | April 2013 | April 2017 |
| NCT03185494 | Unknown status | Phase 1/Phase 2 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | August 1, 2017 | August 1, 2020 |
| NCT01558778 | Withdrawn | N/A | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | May 2012 | |
| NCT02662296 | Withdrawn | Phase 2 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | March 2016 | |
| NCT02285244 | Withdrawn | Phase 2 | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation | March 12, 2015 | March 12, 2015 |
- Disase is a (Disease Ontology)
- DOID:1040
- Cross Reference ID (Disease Ontology)
- ICDO:9832/3
- Cross Reference ID (Disease Ontology)
- MESH:D015463
- Cross Reference ID (Disease Ontology)
- NCI:C3181
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:110006004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023486
- Exact Synonym (Disease Ontology)
- PLL
- Exact Synonym (Disease Ontology)
- Prolymphocytic leukaemia